GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Champions Oncology Inc (STU:2I3) » Definitions » Cyclically Adjusted Price-to-FCF

Champions Oncology (STU:2I3) Cyclically Adjusted Price-to-FCF : (As of Jun. 04, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Champions Oncology Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Champions Oncology Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Champions Oncology's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Champions Oncology Cyclically Adjusted Price-to-FCF Chart

Champions Oncology Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Champions Oncology Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Champions Oncology's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Champions Oncology's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Champions Oncology's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Champions Oncology's Cyclically Adjusted Price-to-FCF falls into.


;
;

Champions Oncology Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Champions Oncology's Cyclically Adjusted FCF per Share for the quarter that ended in Jan. 2025 is calculated as:

For example, Champions Oncology's adjusted Free Cash Flow per Share data for the three months ended in Jan. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jan. 2025 (Change)*Current CPI (Jan. 2025)
=0.033/134.0288*134.0288
=0.033

Current CPI (Jan. 2025) = 134.0288.

Champions Oncology Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201504 -0.212 99.824 -0.285
201507 -0.269 100.691 -0.358
201510 -0.266 100.346 -0.355
201601 -0.091 99.957 -0.122
201604 -0.071 100.947 -0.094
201607 -0.226 101.524 -0.298
201610 -0.011 101.988 -0.014
201701 -0.071 102.456 -0.093
201704 -0.014 103.167 -0.018
201707 -0.226 103.278 -0.293
201710 0.018 104.070 0.023
201801 0.028 104.578 0.036
201804 -0.015 105.708 -0.019
201807 0.008 106.324 0.010
201810 -0.013 106.695 -0.016
201901 0.076 106.200 0.096
201904 0.007 107.818 0.009
201907 -0.079 108.250 -0.098
201910 0.041 108.577 0.051
202001 0.007 108.841 0.009
202004 0.074 108.173 0.092
202007 -0.088 109.318 -0.108
202010 0.021 109.861 0.026
202101 -0.060 110.364 -0.073
202104 -0.160 112.673 -0.190
202107 -0.044 115.183 -0.051
202110 0.039 116.696 0.045
202201 0.237 118.619 0.268
202204 0.019 121.978 0.021
202207 -0.069 125.002 -0.074
202210 0.201 125.734 0.214
202301 0.056 126.223 0.059
202304 -0.098 127.992 -0.103
202307 -0.312 128.974 -0.324
202310 0.036 129.810 0.037
202401 -0.068 130.124 -0.070
202404 -0.124 132.289 -0.126
202407 0.020 132.708 0.020
202410 -0.019 133.182 -0.019
202501 0.033 134.029 0.033

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Champions Oncology  (STU:2I3) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Champions Oncology Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Champions Oncology's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Champions Oncology Business Description

Industry
Traded in Other Exchanges
Address
One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

Champions Oncology Headlines

No Headlines